Fifth Third Bancorp
IMDX

Fifth Third Bancorp’s Insight Molecular Diagnostics IMDX Stock Holding History

Fifth Third Bancorp’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-11
Closed -$2K – 2332
2017
Q3 		$2K Hold
11
– – ﹤0.01% 2046
2017
Q2 		$1K Hold
11
– – ﹤0.01% 2135
2017
Q1 		$1K Hold
11
– – ﹤0.01% 2055
2016
Q4 		$1K Hold
11
– – ﹤0.01% 2134
2016
Q3 		$1K Hold
11
– – ﹤0.01% 2160
2016
Q2 		$1K Hold
11
– – ﹤0.01% 2184
2016
Q1 		$1K Buy
+11
New +$974 ﹤0.01% 2247

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fifth Third Bancorp's IMDX Position: Q4 2017 in Review

Fifth Third Bancorp sold out of Insight Molecular Diagnostics (IMDX) in Q4 2017, closing a stake of 11 shares — an estimated $2K sold.

Fifth Third Bancorp first reported a position in IMDX in Q1 2016 and held it in 7 quarters. The position peaked at $2K in Q3 2017. 45 funds tracked by Wall St. Rank hold IMDX as of Q4 2017.

  • Fifth Third Bancorp reported no remaining Insight Molecular Diagnostics position as of Q4 2017 after selling out during the quarter.
  • Fifth Third Bancorp sold 11 Insight Molecular Diagnostics shares in Q4 2017, an estimated $2K.
  • Fifth Third Bancorp first reported a position in Insight Molecular Diagnostics in Q1 2016 and held it in 7 quarters.
  • Fifth Third Bancorp's Insight Molecular Diagnostics position peaked at $2K in Q3 2017.
  • 45 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2017.

Based on Fifth Third Bancorp's 13F filing for Q4 2017, filed 14 Feb 2018.